Stay updated with breaking news from Frederic triebel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer patients expressing PD-L1. ....
Immutep to Participate in November Investor Events tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Media Release Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with low PD-L1 expression (TPS 1-49%), and has not been reached in patients with high PD-L1 expression (TPS >50%), exceeding expectationsPromising Overall Survival, Overall Response Rate, Progression Free Survival, and Duration of Response visible across all PD-L1 subgroups (TPS <1%, ≥1%, 1-49%, and ≥50%), differen ....
Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur. ....
Immutep (IMMP) Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.